PO.PR01.01 · 预防研究
在全球范围内实现前列腺癌公平：iCCaRE联盟的多国进展
Achieving prostate cancer equity globally: Multinational advances from the iCCaRE consortium
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：非洲侨民群体中的黑人男性承受着不成比例的前列腺癌（CaP）负担。包容性癌症照护研究公平（iCCaRE）联盟旨在通过全球科学合作、创新研究、社区参与式干预和下一代人才培养来消除CaP负担。该联盟的主要目标是通过研究、研究培训与教育、社区参与和社区外展，优化CaP的诊断、治疗和生存期照护。该联盟整合了数字健康技术、社区导航、精准沟通和精准科学。
方法：在北美和非洲的合作机构启动了五个完整项目和一个试点项目。在多个核心平台和服务的支持下，研究活动包括：（1）实施前列腺癌诊断即时虚拟机器人助手（PPCD-ViRA）；（3）启动居家癌症照护试验；（4）加勒比海和撒哈拉以南非洲移民的移民健康研究；（5）扩展基因组学和代谢组学研究；以及（6）数字、心理社会和生存期干预的开发。通过iCCaRE TV、网络研讨会以及包括全球前列腺健康对话（Glo-PHD）在内的社区参与项目开展了培训和传播活动。
结果：在一年内，成果包括45场报告、17篇出版物、16份基金申请和3个奖项。联盟提供了408次现场网络研讨会互动，并通过Glo-PHD在全球范围内覆盖了400多名男性。PPCD-ViRA已完全开发完成并准备好临床部署（参见https://www.youtube.com/watch?v=1mI-HS5R6sk）。用于基因组和代谢组分析的非洲队列扩展已在多个国家启动，生物样本采集正在进行中。媒体传播在各平台产生了超过15,000次观看，包括高影响力的教育视频（参见：www.youtube.com/@iCCaREConsortium）。培训成果包括13名早期职业研究者和7名受训的前列腺癌倡导者。
结论：在短短一年内，iCCaRE联盟第2阶段在全球范围内推动CaP公平的转型方面取得了实质性进展。通过多学科科学、数字创新和社区伙伴关系，联盟正在构建可扩展的基础设施，以应对黑人男性的诊断体验、治疗质量和生存期照护问题。持续的努力将继续推进精准医学、根植于文化的干预措施和全球能力建设。
查看英文原文 English abstract
Background: Black men across the African Diaspora experience a disproportionate burden of prostate cancer (CaP). The Inclusive Cancer Care Research Equity (iCCaRE) Consortium aims to eliminate CaP burden through global scientific collaboration, innovative research, community-engaged interventions, and next-generation workforce development. The primary objective for this Consortium was to optimize CaP diagnosis, treatment, and survivorship through research, research training and education, community engagement and community outreach. The Consortium integrates digital health technologies, community navigation, precision communication and precision science.
Methods: Five full projects and one pilot project were launched across partner institutions in North America and Africa. Supported by multiple cores and services, the research activities included (1) implementation of a Point of Prostate Cancer Diagnosis Virtual Robot Assistant (PPCD-ViRA); (3) initiation of a cancer care at home trial; (4) migrant health studies of Caribbean and Sub-Saharan African immigrants; (5) expansion of genomic and metabolomic research; and (6) digital, psychosocial, and survivorship intervention development. Training and dissemination activities were deployed through iCCaRE TV, webinars, and community engagement programs including the Global Prostate Health Dialogue (Glo-PHD).
Results: In one year, accomplishments included 45 presentations, 17 publications, 16 grant submissions, and 3 awards. The consortium delivered 408 live webinar engagements and reached more than 400 men globally through Glo-PHD. PPCD-ViRA was fully developed and prepared for clinical deployment (see https://www.youtube.com/watch?v=1mI-HS5R6sk). The African cohort expansion for genomic and metabolomic profiling was activated across several countries, with biospecimen collection underway. Media dissemination generated more than 15,000 views across platforms, including high-impact educational videos (see: www.youtube.com/@iCCaREConsortium). Training achievements included 13 early-career investigators and 7 trained prostate cancer advocates.
Conclusions: In just one year, the iCCaRE Consortium Phase 2 made substantial progress toward transforming CaP equity globally. Through multidisciplinary science, digital innovation, and community partnerships, the consortium is building scalable infrastructure to address diagnosis experiences, treatment quality, and survivorship among Black men. Ongoing efforts will continue to advance precision medicine, culturally grounded interventions, and global capacity building.
利益披露 Disclosure
F. T. Odedina, None..
C. Mahin, None.